Collaboration and License Agreements (Tables)

3 Months Ended

Jun. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Collaboration and License Agreements

The following table presents changes in the Company’s contract assets and liabilities during the three months ended June 30, 2021 (in thousands):

	Balance at March 31, 2021		Additions		Imputed Interest		Deductions		Balance at June 30, 2021
Contract assets:
Milestone receivable from Pfizer	$	—	$	100,000	$	—	$	—	$	100,000
Contract liabilities:
Deferred revenue (1)	$	497,933	$	100,000	$	—	$	(29,509)	$	568,424
Cost share advance from Pfizer (2)	$	121,862	$	—	$	601	$	(18,285)	$	104,178

(1) Includes $117.2 million and $451.2 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of June 30, 2021. Includes $100.6 million and $397.4 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2021.

(2) Includes $104.2 million presented as current on the unaudited condensed consolidated balance sheet as of June 30, 2021. Includes $92.4 million and $29.4 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2021.